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Summary. 
A deficiency of the enzyme adenosine deamin- 
ase is associated with an autosomal recessive 
form of severe combined immunodeficiency dis- 
ease in man. The molecular forms of the normal 
human enzyme have now been well charac- 
terized in an effort to bet ter  understand the 
nature of the enzyme defect in affected patients. 
In some human tissues adenosine deaminase 
exists predominantly as a small molecular form 
while in other tissues a large form composed of 
adenosine deaminase (small form) and an 
adenosine deaminase-binding protein predomi- 
nates. The small form of the enzyme purified to 
homogenei ty by antibody affinity chromatog- 
raphy is a monomer  of native molecular weight 
of 37,600. The adenosine deaminase-binding 
protein, purified by adenosine deaminase affinity 
chromatography, appears to be a dimer of 
native molecular weight 213,000 and contains 
carbohydrate. Based on direct binding measure- 
ments, chemical cross-linking studies and 
sedimentation equilibrium analyses, small form 
adenosine deaminase has been shown to com- 
bine with purified binding protein in a molar 
ratio of 2 :1  respectively to produce the large 
form adenosine deaminase. 
Reduced, but widely ranging levels of 
adenosine deaminating activity, have been re- 
ported in various tissues of adenosine deamin- 
ase deficient patients. Further,  the characteris- 
tics of this residual enzyme activity have been 
analyzed immunochemically to substantiate 
genetic heterogeneity in this disorder. 
While many types of immunodeficiency are 
currently recognized in man, in most cases the 
molecular defect is unknown. The discovery of a 
deficiency of the enzyme, adenosine deaminase, 
ADA,  (EC 3.5.4.4), in some patients with 
severe combined immunodeficiency disease rep- 
resented an early clue to the pathogenesis of 
immune dysfunction at the molecular level 1 4. 
Affected patients with markedly reduced levels 
of A D A  exhibit a defect of both cellular and 
humoral immunity characterized clinically by 
severe recurrent  infections with a fatal outcome 
if untreated. Attempts to elucidate the nature of 
the genetic mutation(s) leading to the reduction 
of A D A  activity in these immunodeficient pa- 
tients have been complicated in part by an 
incomplete understanding of the nature of A D A  
in normal tissues. In this review we will consider 
the structural characteristics of the normal and 
mutant  forms of A D A  as they are currently 
understood. 
Molecular Heterogeneity 
Studies of A D A  from a variety of normal 
human tissues have provided evidence for sub- 
stantial molecular heterogeneity. The enzyme in 
erythrocytes has been reported to have a 
molecular weight in the range of 31,000 to 
38,000 5 8 and to exhibit genetically determined 
polymorphism detectable by electrophoresis 5. In 
other  normal human tissues, two additional 
molecular forms of the enzyme with apparent 
molecular weights of 280,000 and 440,000 have 
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been described 9. In addition, electrophoretically 
distinct isozymes of A D A  characteristic for a 
given tissue have been reported. These observa- 
tions led EDWARDS, e l  al. 9 to suggest that the 
small form and large forms of the enzyme were 
coded for by different genes. 
The relationship between the molecular and 
electrophoretic forms of A D A  became better 
understood with the observation that a specific 
protein termed "conversion factor" could ap- 
parently convert the small molecular form of 
A D A  into the large molecular form 1°. Further- 
more, it was observed that a patient with A D A  
deficiency and severe combined immuno- 
deficiency disease lacked both the small and the 
large form of A D A  activity in all tissues 
suggesting that both forms of the enzyme were 
coded for by the same structural gene 11. This 
finding was supported by the autosomal assign- 
ment of A D A  exclusively to chromosome 2012. 
Finally, the addition of normal small form 
erythrocyte A D A  to various tissue extracts from 
an A D A  deficient patient led to the production 
of the corresponding, characteristic large "tissue 
specific" electrophoretic form of the enzyme. 
These data further supported the one gene 
hypothesis for A D A  and demonstrated the 
presence of "conversion factor(s)" in a variety 
of human tissues 13. 
In recent studies in our laboratory, we have 
examined the nature of the multiple molecular 
forms of A D A  in normal human tissues. In 
some tissues, e.g. stomach, spleen and small 
intestine, A D A  exists exclusively as the small 
molecular weight form (Mr = 36,000) while in 
other tissues, e.g. lung and kidney, the large 
molecular weight form (Mr = 298,000) predomi- 
nates 14. In general, the small form A D A  pre- 
dominates in tissue extracts exhibiting high 
enzyme specific activity and no detectable "con- 
version activity" while the large form of the 
enzyme predominates in tissue extracts exhibit- 
ing lower enzyme specific activities and abun- 
dant "conversion activity ''14. 
An examination of the subcellular distribution 
of A D A  in human leucocyte preparations has 
indicated that the majority of the A D A  activity 
is soluble (100,000 x g fraction) while approxi- 
mately 2% of the total activity appeared to be 
particulate (6,000 x g fraction) suggesting that at 
least a small fraction of A D A  is membrane 
associated TM. The characteristics of the putative 
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membrane associated A D A  and its possible 
significance have not been explored further. 
However,  examination of the soluble molecular 
species of A D A  has shown that both forms of 
the enzyme are interconvertible. Under  de- 
naturing conditions, the large form A D A  can be 
converted to the small form of the enzyme with 
release of the "conversion factor".  The small 
form A D A  can be converted to the large form 
of the enzyme in the presence of tissue extracts 
containing the A D A  "conversion factor ''14. 
We have purified both human small form 
A D A  and the A D A  "conversion factor" to 
homogeneity in order to further examine their 
characteristics and the nature of their associa- 
tion. 
Nature of Small Form Ademosine Deaminase 
The small form of human A D A  was purified 
from erythrocytes to apparent homogeneity 
using antibody affinity chromatography 8. As 
shown in Table 1, the enzyme was purified 
800,000-fold from crude hemolysate to a final 
specific activity of 538/xmol/min/mg. The key 
step in this purification scheme was the use of 
anti-calf A D A  antibody affinity chromatog- 
raphy. To our advantage, antiserum produced 
against commercially available calf A D A  cross- 
reacted with the human enzyme, allowing us to 
use this highly selective interaction as part of 
our initial purification scheme. 
Native polyacrylamide gel electrophoresis of 
this highly pure preparation revealed that the 3 
major  electrophoretic forms of A D A  copurified 
using this isolation technique (Fig. 1A). Sodium 
dodecyl sulfate (SDS) polyacrylamide gel elec- 
trophoresis of this purified preparation revealed 
one major protein band by Coomassie stain 
(Fig. 1B) indicating that the electrophoretically 
different forms of A D A  were of the same 
molecular size. The apparent subunit molecular 
weight calculated from SDS gels (Mr = 41,700) 
agreed well with the native molecular weight 
calculated from the S2o,w and Stokes radius 
(Mr = 37,600) and sedimentation equilibrium 
analysis (Mr = 37,500), suggesting the small 
form of enzyme to be monomeric 8,~s. 
The highly purified small form A D A  was 
estimated to have less than 10% carbohydrate 
content based on a periodic acid-Schiff stain. 
Table 1 
Purification of human erythrocyte adenosine deaminase 
Volume Total activity Total protein Specific activity Purification Recovery 
Step ml nmol/min x l0 s mg nmol/min/mg -fold % 
Crude hemolysate 
diluted 1 : 3 12,672 10.2 1.52 x 106 0.673 1 100 
1. pH adjust 5.8 13,526 10.2 1.16x 106 0.881 1.3 100 
2. CM-Sephadex 
batch treatment 12,626 8.78 3.53 x 10 ~ 24.9 37 86 
3. 0-60% [NH4]2SO 4 362 8.22 1.21× 10 4 67.5 100 80 
4. Affinity 
chromatography 0.5 3.63 0.675 538,400 800,000 35 
(from Reference 8). 
Fur ther ,  the ca rbohydra te  por t ion  of small fo rm 
A D A  showed a specific react ion with lotus 
lectin indicating the presence  of a terminal  
L- fucose  residue on the molecule  s. Nevertheless  
the chemical,  or  structural  differences, or  both,  
responsible  for  the three e lec t rophoret ic  forms 
of h u m a n  small fo rm A D A  remain  to be 
established. 
The  purified small fo rm A D A  has a b road  p H  
o p t i m u m  f rom 6 to 8, exhibits a K m  for  
adenosine  of 52 tXM, a Ki for  inosine of 700 ~M, 
a Stokes radius of  24 A and an S2o,w of 
3.8 x 10 13s. These  proper t ies  were  found  to be 
identical to those of impure  prepara t ions  of the 
enzyme  f rom several different tissue sources 8"14. 
The  selected compounds ,  A M P ,  d A M P ,  cAMP,  
A D P ,  d A D P ,  A T P ,  d A T P ,  cytosine, cytidine, 
CMP,  dCMP,  CDP,  dCDP,  CTP and d C T P  and 
S-adenosy lhomocys te ine  had no inhibi tory affect 
on  the highly purified A D A ,  while adenine and 
6 -me thy lmercap topur ine  r ibonucleoside had a 
marked  inhibi tory effect s . 
SCrimmagER e t  al .  7 have also purified h u m a n  
ery throcyte  A D A  to homogene i ty  utilizing a 
purification scheme different f rom ours. The  key 
step in their p rocedure  involved an adenosine  
Sepharose  affinity co lumn technique.  The  re- 
por ted  molecular  proper t ies  of purified ery thro-  
cyte A D A  isolated by their me thod  were similar 
to  those descr ibed above. 
Fig. 1. Polyacrylamide gel electrophoresis of purified eryt- 
hrocyte ADA. A. Native 5% polyacrylamide gel, pH 8.3. 
One gel was stained with Coomassie blue and scanned at 
562 nm while a companion gel was sliced and assayed for 
enzyme activity. B. SDS-10% polyacylamide gel stained 
with Coomassie blue (from reference 8). 
Nature of the Adenosine Deaminase-Binding 
Protein ("Conversion Factor") 
O u r  initial studies were designed to character ize 
the  role of the "convers ion  fac tor"  in conver t ing 
the small form A D A  to the large molecular  
fo rm of the enzyme.  The  apparen t  convers ion 
process was found  to p roceed  almost  equally as 
well at 37 °C or  4 °C and was associated with 
loss of "conver t ing  activity ''14. Further ,  under  
mild denatur ing  conditions,  the large fo rm of 
the enzyme yielded the small fo rm A D A  and 
some detectable  "conver t ing  activity ''14. These  
data  suggested a non-enzymat i c  process 
whe reby  the "conver t ing  fac tor"  might  be bind- 
ing directly to small fo rm A D A  leading to the 
synthesis of large form. Indeed,  following these 
initial studies, we demons t r a t ed  that  "conver -  
sion fac tor"  activity in h u m a n  kidney would  
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Table 2 
Purification of human adenosine deaminase binding protein 
Volume Total activity Total protein Specific activity Purification Recovery 
Step ml g mol/min mg tx mol/min/mg -fold % 
1. Crude Kidney 
Supernatant 520 823 12,776 0.064 1 100 
2. DEAE-Cellulose 
Chromatography 146 559 2,800 0.20 3.1 68 
3. Affinity Chroma- 
tography 1.9 245 2.27 108 1,687 30 
(from Reference 16). 
bind to small form ADA covalently linked to 
Sepharose gel and that this binding activity 
could be eluted from the column under mild 
denaturing conditions. Since this ADA-binding 
factor was further shown to be a protein, we 
have adopted the more appropriate term ADA- 
binding protein. To further characterize this 
ADA-binding protein, we have purified the 
protein to homogeneity and then studied its 
properties and the nature of its association with 
ADA. 
Human kidney ADA-binding protein was 
purified to apparent homogeneity by a two-step 
process 16. As shown in Table 2, the binding 
protein was purified approximately 1,700-fold 
from crude kidney extract to a specific activity 
of 108 units of large form ADA activity/rag 
protein. The use of an affinity column contain- 
ing calf ADA bound to polyacrylamide beads 
proved to be both a convenient and highly 
specific step in this purification. Since human 
small form and calf small form ADA were 
found to bind equally well to human ADA- 
binding protein, it was possible to use the calf 
enzyme for affinity purification of human bind- 
ing protein. This was fortuitous since calf ADA 
was found to be more stable than the purified 
human small form enzyme and further could be 
obtained commercially in relatively pure form at 
low cost. 
Analysis of the highly purified ADA-binding 
protein by native polyacrylamide gel elec- 
trophoresis revealed one protein band by 
Coomassie stain (Fig. 2A) coincident with 
ADA-binding protein activity as determined by 
assay of a companion gel (data not shown). 
SDS-polyacrylamide gel electrophoresis of 
purified ADA-binding protein also revealed 
only one protein band by Coomassie stain (Fig. 
2B) with a calculated subunit molecular weight 
of 106,000. 
The purified ADA-binding protein was shown 
to have a native molecular weight of 213,000 by 
sedimentation equilibrium analysis 15 and based 
on its subunit molecular weight appeared to be 
a dimer of identical subunits 16. In addition, an 
SDS-polyacrylamide gel stained positive with 
the periodic acid-Schiff method and fluorescent 
dansylhydrazine, suggesting the presence of car- 
bohydrate on the molecule (Fig. 2C). The 
Fig. 2. Polyacrylamide gel electrophoresis of purified ADA- 
binding protein. A. Native 5% polyacrylamide gel, pH 8.3 
stained with Coomassie blue. B. SDS-5% polyacrylamide 
gel stained with Coomassie blue. C. SDS-5% polyac- 
rylamide gel stained with periodic acid-Schiff reagent using 
dansylhydrazine (from reference 16). 
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nature of the carbohydrate moiety of human 
kidney ADA-binding protein was further 
analyzed using a variety of lectins. The highly 
pure ADA-binding protein was found to react 
specifically only with the lectins, ricin and 
phytohemagglutinin, suggesting an internal link- 
age of/3-galactose-/3-N-acetyl galactose in the 
carbohydrate portion of the molecule. Failure of 
the kidney ADA-binding protein to react with 
the lectin, wheat germ agglutinin, suggested that 
sialic acid residues were not present on the 
molecule. 
On several occasions we have also found that 
electrophoresis of purified ADA-binding protein 
on 5% SDS polyacrylamide gels revealed 2 
subunit molecular weight species of 106,000 
and 94,000 when stained for protein with 
Coomassie ~6. The appearance of this lower 
subunit molecular weight species has also been 
observed on 5% SDS gels after storage of the 
native protein for several weeks at 4 °. When a 
companion SDS gel was stained for carbohyd- 
rate, it was found that the lower subunit 
molecular weight species of the ADA-binding 
protein was markedly deficient in carbohydrate 
content suggesting that it was most probably a 
degradation product of the higher subunit 
molecular weight species. However, purified 
ADA-binding protein preparations were found 
to be free of detectable glycosidase activities 
indicating that this degradation mechanism may 
be non-catalytic. 
SCHRADZR et al. 17, using a purification method 
similar to ours, have also reported purified 
ADA-binding protein (termed complexing pro- 
tein) to be a dimer of native molecular weight 
200,000 with subunit molecular weights esti- 
mated to be 97,000 and 85,000. 
Stoichiometry of the Large Form Complex 
The studies cited above established that the 
large form ADA was composed of small form 
ADA and the ADA-binding protein. An 
analysis of the stoichiometry of the large 
molecular form of ADA (the ADA-binding 
protein complex) was performed in our labora- 
tory using several different methods including 
direct binding, chemical cross-linking and 
sedimentation equilibrium analyses ~5. 
The stoichiometry of the large form ADA 
was first analyzed by direct binding experiments. 
The extent of binding between 125I-labeled 
small form ADA and varying amounts of 
purified binding protein could be followed con- 
veniently by separation of the substrates and 
product of the binding reaction on polyacryl- 
amide gels followed by quantitation of gel 
segments by gamma counting is. The binding 
reaction between small form ADA and binding 
protein was found to be complete within 
10 min. at 37 °C, to proceed over a broad pH 
range of 5 to 8 and to be unaffected by changes 
in ionic strength (0-200 mM KC1), azide 
(0.02%), thiols (5 mM), divalent metal ions 
(5 mM) and bovine serum albumin (1- 
25 mg/ml) 14'1s. Various purine nucleosides and 
nucleotides including adenosine, inosine, AMP, 
IMP, GMP, cAMP, ATP, cGMP and GTP at 
various concentrations had no apparent effect 
on the binding reaction TM. As shown in Figure 3, 
a Scatchard-type plot of our direct binding data 
indicated that 2.15 moles of small form ADA 
were bound to 1 mole of binding protein under 
the conditions of our assay. 
Chemical cross-linking was used as another 
approach to determine the stoichiometry of 
large form ADA. Successful chemical cross- 
linking of large form ADA was dependent upon 
both the accessibility of the reactive groups on 
the component subunits of the native protein 
and the ability of the bifunctional cross-linking 
reagent to bridge between these reactive groups 
on adjacent subunits. If both conditions were 
satisfied, then the number of cross-linked 
species produced for large form ADA should 
theoretically equal the maximum number of 
different combinations of its subunits. 
If large form ADA was composed of 2 moles 
of the monomeric small form ADA (designated 
A, A) and 1 mole of the dimeric binding protein 
(designated BB), then 8 possible cross-linked 
combinations would be theoretically possible: 
BBAA, BBA, BAA, BB, BA, B, AA and A. 
Two types of radiolabeled native large form 
ADA were prepared by either combining ~25I- 
labeled ADA with non-labeled binding protein 
or by combining 125I-labeled binding protein 
with non-labeled ADA. When these 125I-labeled 
native large form ADA molecules were indi- 
vidually cross-linked with glutaraldehyde and 
electrophoresed on SDS polyacrylamide gels, 
the combined data consistently showed 6 differ- 
ent radioactive peaks (see Figure 4). With 
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Fig. 3. Direct binding of small form A D A  to ADA-binding protein. Highly purified binding protein (0.05 tLM, O---Q; 0.10 tzM, 
O - - O )  was added to 12SI-small form ADA (3.6× 109 dpm/pmol) diluted serially from 0.45 tXM. 125I-small form ADA 
(1.8 x 109 dpm/pmol) prepared by dilution with nonradioactive ADA, was also incubated with 0.05/ZM of highly purified 
binding protein ( , t--A} in a similar manner. The molecular weight of small form ADA and binding protein used in these 
calculations was assumed to be 38,000 and 213,000, respectively, based on sedimentation equilibrium analyses data. The inset 
shows a Scatchard-type plot of the data in which r is the number of moles of ADA bound per mole of binding protein and f is 
the concentration of free A D A  (from reference 15). 
reference to authentic samples of binding pro- 
tein and small form ADA, radioactive peaks 
observed at Rf = 0.49 and 0.31 corresponded to 
binding protein monomer (B) and dimer (BB), 
respectively, while the peak at Rf=  0.88 corres- 
ponded to monomeric small form ADA (A). 
The remaining radioactive peaks shown in Figure 
4 observed at Rf=0.40,  0.27 and 0.18 ap- 
peared to represent combinations of both bind- 
ing protein and ADA subunits. 
Since the mobility of each radioactive cross- 
linked species on SDS polyacrylamide gels 
should roughly correlate with its molecular 
weight, this relationship was used to limit the 
possible combinations of A and B subunits 
contained in the 3 coincident radioactive peaks 
present in Figure 4. The radioactive peak at 
Rf = 0.40 (Mr = 145,000) which migrated be- 
tween binding protein monomer (B, Mr = 
106,000, Rf=0.49) and dimer (BB, Mr=  
213,000, Rf = 0.31) would presumably be a BA 
combination of expected molecular weight 
144,000. The peak at Rf = 0.27 (Mr = 250,000) 
present just after the binding protein dimer 
peak (BB, Mr=  213,000, Rf = 0.31), could pos- 
sibly be a BBA combination of expected 
molecular weight 251,000 and finally the peak 
at Rf=  0.18 (Mr = 290,000) could reflect the 
cross-linked native complex, BBAA, of ex- 
pected molecular weight 289,000. A plot of the 
expected molecular weight for the proposed 
cross-linked species versus the log of their Rf 
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Fig. 4. SDS polyacrylamide gel profiles of cross-linked 125I-labeled large form ADA. Samples were cross-linked individually 
with glutaraldehyde for 1½ h and electrophoresed on 3-10% linear gradient cylindrical SDS polyacrylamide gels. Gels were 
sliced into 1,5 mm sections and analyzed for 125I radioactivity: Cross-linked large form ADA prepared with 12sI labeled ADA 
subunits (O--G) and cross linked large form A D A  prepared with 12sI labeled binding protein subunits (I---Q) are shown. The 
putative cross-linked species are indicated by the appropriate letter abbreviations (from reference 15). 
values was found to be linear. Noticeably absent 
in the radioactive gel profile were peaks corres- 
ponding to an AA species and a BAA species. 
This suggested that the distance between the 
two ADA (A) subunits in the native large form 
ADA molecule was too great for successful 
cross-linking under these conditions. If the 
stoichiometry of large form ADA were 1 mole 
of small form ADA and 1 mole of binding 
protein, then 5 cross-linked combinations of the 
subunits would theoretically be possible: BBA, 
BB, BA, B and A. Our data clearly showed 
more cross-linking than this 1 : 1 model would 
predict and thus strongly favored a minimum 
2 : 1 stoichiometry. 
Sedimentation equilibrium analyses revealed a 
molecular weight of 300,000 for large form 
ADA (the ADA-binding protein complex). This 
molecular weight considered with molecular 
weights of 37,500 for small form ADA and 
213,000 for binding protein, would be most 
consistent with the proposed stoichiometry of 2 
moles of small form ADA and 1 mole of 
binding protein for the large form complex. The 
model for the association of small form ADA 
and the ADA-binding protein to produce the 
large form ADA is depicted in Figure 5 and 
indicates our current understanding of both the 
stoichiometry of large form ADA and its appar- 
ent symmetry. 
The molecular weight of the large form ADA 
prepared in vi tro in our experiments compared 
well with previous estimates of the large form 
ADA molecular weight analyzed from several 
different tissue s o u r c e s  14. This suggested that 
the stoichiometry of the large form ADA 
complex may be constant regardless of the 
tissue source of the enzyme or the "tissue 
specific" isozyme present. It has been proposed 






Fig. 5. Proposed model for the formation of the large 
molecular form of ADA. Based on direct binding experi- 
ments and sedimentation equilibrium analyses, it appears 
that 2 moles of monomeric small form ADA (Mr = 38,000) 
combine with 1 mole of the dimeric ADA-binding protein 
(Mr= 213,000) to produce 1 mole of the large form ADA 
complex (Mr = 300,000). Scatchard analysis and chemical 
cross-linking indicates that the binding protein has only one 
small form ADA binding site per subunit and that these 
binding sites are apparently non-interacting and geometri- 
cally distance from one another. With a calculated dissocia- 
tion constant (Kd) of 2.8 x 10 =s M, the large form ADA 
complex may dissociate spontaneously at low physiological 
concentrations to produce the small form of the enzyme and 
the ADA-binding protein. 
isozymes of large form ADA may reflect the 
association of the small form ADA with a 
"tissue specific" ADA-binding protein of 
heterogeneous carbohydrate content. It has 
been suggested that probably the sialic acid 
content of the binding protein present in a given 
tissue may contribute to the electrophoretic 
properties of the corresponding large form 
ADA produced; however, it should be noted 
that treatment of tissue extracts with 
neuraminidase does not alter the molecular 
form or molecular weight of the large form 
complex 18. 
Although we have characterized the physical 
and chemical properties of ADA and its binding 
protein in some detail, at present the physiolog- 
ical significance of this association still remains 
obscure. Our early observation of an inverse 
relationship between the specific activity of 
ADA in crude tissue extracts and the concen- 
tration of the ADA-binding protein suggested a 
possible inhibitory or regulatory function for the 
binding protein TM. However using purified frac- 
tions, the interaction of binding protein with 
small form ADA did not appear to alter the 
kinetic properties of the enzyme i.e., the Vmax, 
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Km for adenosine, and Ki for inosine remain 
identical even in the presence of a 100-fold 
molar excess of the binding protein 16. While the 
ADA-binding protein does not appear to di- 
rectly affect the kinetic properties of ADA, the 
possibility still exists that the binding protein 
may regulate the level of ADA activity in vivo. 
In a given tissue, the "tissue specific" ADA- 
binding protein(s) may function by either alter- 
ing the rate of synthesis and/or degradation or 
by influencing the intra-cellular location and/or 
intracellular transport of ADA. All of these 
possibilities, however, remain to be examined. 
Alternatively or in addition, the possibility also 
exists that ADA might be regulating a still to be 
defined function(s) of the binding protein. Based 
on a literature search for proteins with similar 
physical characteristics to our ADA-binding 
protein, the enzyme S-adenosylhomocysteine 
hydrolase (EC3.3.1.1) appeared as an interest- 
ing candidate for our ADA-binding protein. 
This enzyme has been shown to be required for 
the hydrolysis of S-adenosylhomocysteine to 
produce adenosine and homocysteine 19. Since 
S-adenosylhomocysteine hydrolase (also termed 
the adenosine binding protein) is strongly inhi- 
bited by adenosine, the hydrolysis reaction in 
vivo would be highly dependent upon the 
removal of adenosine by ADA. Thus an associ- 
ation between these two enzymes would be 
logical. We have monitored the activity of 
S-adenosylhomocysteine hydrolase and our 
ADA-binding protein through the purification 
scheme of binding protein in human kidney and 
found unfortunately that both activities were 
separate and distinct a°. 
We have also begun to search in other 
directions to try to establish the identity and/or 
function of the ADA-binding protein. We have 
observed that human serum contains predomin- 
antly the large molecular form of ADA and that 
detectable binding protein activity is also pres- 
ent z°. This finding coupled with the recent 
observation that the human ADA binding pro- 
tein is coded for on chromosome 621 led us to 
speculate that binding protein might be related 
to one of the HLA antigens or might have some 
intrinsic immunoregulatory function. Therefore, 
in preliminary experiments, we have begun to 
assess the affects of binding protein on lympho- 
cyte function. In our initial studies, we have 
been unable to detect any inhibition or other 
effects on P H A  stimulation of lymphocytes in 
the presence of binding protein concentrations 
as high as 100 times the level normally found in 
serum a°. However,  further experiments in this 
direction are in progress. 
We have also tried to determine whether the 
ADA-binding protein might associate with some 
other human tissue proteins in addition to 
ADA.  This possibility was tested by two differ- 
ent techniques. First, using a column containing 
binding protein attached to Sepharose, we 
established that A D A  could be bound and 
detected. Then various human tissue extracts 
were individually passed through the column 
e.g., spleen, kidney, stomach, and small intes- 
tine. The column was then washed, eluted with 
urea and the eluate analyzed by SDS- 
polyacrylamide gel electrophoresis. Within the 
sensitivity of this method, no protein other than 
small form A D A  appeared to associate with 
binding protein coupled to the column. Using 
an alternative approach, 12SI-labeled binding 
protein was incubated with an individual tissue 
extract and the mixture resolved by either 
sucrose gradient ultracentrifugation or Sephadex 
G-200 column chromatography. Again using 
tissue extracts of spleen, kidney, stomach and 
small intestine only radioactive peaks corres- 
ponding to binding protein or large form A D A  
(ADA-binding protein complex) could be de- 
tected, confirming the specificity of the A D A  
binding protein 2°. 
Characteristics of Residual Adenosine 
Deaminase in Patients with Severe Combined 
Immunodeficiency Disease 
A deficiency of A D A  associated with an 
autosomal recessive form of severe combined 
immunodeficiency disease (SCID) has been de- 
scribed in well over 30 patients since the initial 
report  by GmLETr et  al. in 19721. In all cases 
the patients exhibited virtually no enzyme activ- 
ity in their erythrocytes although residual A D A  
activity has been observed in other tissues of 
these patients. 
In an early report  22, splenic tissue of a patient 
with SCID was found to have 0.5% or normal 
A D A  activity. The striking finding in this case 
was that the moleular weight of this enzyme 
activity was 110,000. At  a later date, SClqRADER 
e t  al. a3 found that normal spleen also exhibited 
a similar if not identical adenosine deaminating 
enzyme of M r =  110,000. On the basis of 
immunochemical analysis, sensitivity to the 
competitive A D A  inhibitor erythrohydroxy- 
nonyl adenine (EHNA), Km, and pH optimum, 
it was shown that this aminohydrolase was 
clearly distinct from normal splenic ADA. 
Several studies have suggested that A D A  may 
be structurally altered in some patients with this 
enzyme deficiency. Cultured skin fibroblasts 
from two different patients with SCID revealed 
approximately 1% and 10% of normal A D A  
activity 24. In the latter case, the pH optimum 
and Km appeared normal, but the enzyme 
exhibited altered electrophoretic mobility and 
increased heat stability. In another study, the 
fibroblast cell strains from four different im- 
munodeficient patients were found to have 
about 20% of normal A D A  activity and a 
normal Km for adenosine, however again the 
enzyme activity in these cell strains demon- 
strated altered electrophoretic mobility and in- 
creased heat stability suggesting an altered 
enzyme structure 25. 
In a limited study of three A D A  deficient 
fibroblast cell strains, an immunoassay for A D A  
revealed that one cell strain with trace A D A  
activity had immunoreactive protein (CRM) at a 
level approximately 35% of normal while two 
other A D A  deficient cell strains with less than 
1% enzymatic activity demonstrated less than 
5% of normal CRM 26. In this study however, it 
could not be excluded with certainty that fetal 
calf A D A  in the fibroblast culture media may 
not have been endocytosed by at least one of 
these cell strains. 
In order to more accurately evaluate the 
genetic expression of A D A  in this immune 
disorder, we have developed a specific radioim- 
munoassay for A D A  capable of detecting as 
little as 0.06% of normal CRM. We have used 
this radioimunoassay and an equally sensitive 
A D A  enzymatic assay for the analysis of 
hemolysate samples from 9 heterozygote par- 
ents and 4 unrelated children with A D A  defi- 
ciency and SCID 27. 
Table 3 shows the characteristics of erythro- 
cyte A D A  in hemolysates from normal, 
heterozygous and homozygous deficient sub- 
jects. A D A  activity for 18 normal adults and 5 
normal children was found to be 0 .88+0.25 and 
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Table 3 
Characterization of erythrocyte adenosine deaminase 
Hemolysate* Sp. Act. ng CRM/mg Abs. Sp. Act. 





0.88 + 0.24** 1.67 ~: 0.60 563 --46 
(0.53-1.20) (0.90-2.23) (531-620) 
0.86 + 0.26 1.55 -4- 0.50 553 -4-14 
(0.62-1.20) (1.07-2.22) (540-572) 
Heterozygote 
R.M. 1.35 2.40 
D.M. 0.29 0.54 
T.T. 0.74 1.47 
E.B. 0.56 1.25 
La.L. 0.68 1.16 
L.L. 0.41 0.72 
M.H. 0.56 0.94 
F.H. 0.60 1.12 
R.W. 0.33 1.02 
Homozygote 
R.M., Jr. <0.8x 10 -3 <0.001 
B.W. <0.8 x 10 -3 0.007 
E.M. <0.8 x 10 -3 0.052 












* Protein concentrations for hemolysates ranged from 287-156 mg/ml. 
** Mean +1 S.D., range given in parenthesis. 
(from Reference 27). 
0.86 + 0.26 nmol/min/mg hemolysate protein, 
respectively. Using the radioimmunoassay,  the 
quantity of A D A  immunoreact ive protein 
(CRM) was determined to be 1.67 +0 .60  and 
1.55 +0 .50  ng CRM/mg hemolysate  protein and 
the mean absolute specific activity was calcu- 
lated to be 563:546 and 5 5 3 + 1 4  txmol/min/mg 
C R M  for normal adults and children, respec- 
tively. The calculated absolute specific activities 
compared  well with the value of 
5 38 ixmol/min/mg previously reported for 
homogeneous  erythrocyte A D A  8. The  close 
agreement  between the calculated and authentic 
absolute specific activity of A D A  proVided 
further evidence for the accuracy of our 
radioimmunoassay used in conjunction with the 
A D A  enzymatic assay and confirmed the ab- 
sense of systematic error. 
As noted in Table 3, A D A  enzymatic activity 
varied substantially f rom 0.53-  
1.20 nmol/min/mg hemolysate  protein as did the 
level of A D A  C R M  (0.9-2.23 ng/mg hemo-  
lysate protein) for the 18 normal  adult hemo-  
lysates analyzed. However ,  the level of enzyme 
activity and C R M  for each sample showed a 
good correlation suggesting that  the catalytic 
activity per  molecule of A D A  was similar while 
the concentration of A D A  varied in each of the 
normal  hemolysate samples. 
The specific activity of A D A  in the hemo-  
lysates of the heterozygous parents ranged f rom 
0.29 to 1.35 nmol/min/mg with several samples 
falling within the normal adult range while the 
quantity of A D A  C R M  among these samples 
also showed a wide range (Table 3). However ,  
the calculated absolute specific activity for A D A  
0xmol/min/mg CRM) in the majori ty of 
hemolysates from heterozygotes appeared to fall 
within the normal range. Samples E.B., T.T. 
and R.W. were the exceptions with calculated 
absolute specific activities at least 1 S.D. below 
the normal adult mean. C R M  in these three 
heterozygote hemolysates showed the same 
affinity toward A D A  antibody as did the normal 
erythrocyte enzyme. Further  analysis of the 
A D A  from these subjects revealed a normal  
K m  for adenosine and complete inhibition of 
enzyme activity in the presence of the competi-  
tive enzyme inhibitor erythrohydroxynonyl  
adenine (EHNA).  
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Variable genetic expression of the "silent" or 
apparently defective ADA allele(s) was even 
more apparent in the hemolysate of the 
homozygous deficient subjects. The hemolysates 
from homozygous ADA deficient subjects all 
showed undetectable enzyme activity of 
<0.09% of the normal mean activity (represent- 
ing the lower limit of our enzymatic assay) 
(Table 3). Enzyme activity resulting from mixing 
normal and ADA deficient hemolysate was 
additive, suggesting the absence of an ADA 
inhibitor in these samples. 
The hemolysate of R.M. Jr., the child of 
D.M. and R.M., failed to exhibit any detectable 
CRM, i.e., less than 0.06% of mean CRM for 
normal children, consistent with the calculation 
of a normal absolute specific activity for ADA 
in the hemolysate of both parents (R.M. and 
D.M.). In this family, the data suggested that 
only the "normal" ADA allele was expressed in 
the hemolysate of the parents while the inher- 
ited "silent" or defective allele from both 
parents did not produce a gene product im- 
munologically detectable by this antiserum or 
alternatively produced a gene product which 
may have been rapidly degraded in vivo. The 
hemolysates of B.W., E.M. and M.H., however, 
all had easily detectable quantities of ADA 
CRM ranging from 0.4% to 5.6% of the normal 
child mean CRM. 
From this limited number of samples, 
heterozygous and homozygous hemolysates 
from 5 of the 8 total families analyzed revealed 
apparent variable genetic expression of the 
"silent" or defective ADA allele(s). Further, 
hemolysate from some heterozygous subjects 
had quantities of the normal gene product 
which brought total enzyme quantities to a 
normal mean level suggesting possible autolog- 
ous regulation of ADA in the reticulocytes of 
these subjects. 
Further studies on the nature of the genetic 
defect associated with ADA deficiency should 
involve detailed structural analysis of the en- 
zyme gene product. In cases that permit, purifi- 
cation and peptide mapping of the mutant forms 
of ADA could provide the first direct evidence 
for a structural defect in the primary sequence 
of the ADA molecule. In addition, analysis of 
the rate of synthesis and degradation of the 
enzyme in normal and ADA deficient fibroblast 
or lymphoblast cell lines might allow a better 
understanding of the observed variable levels of 
the enzyme noted among different subjects and 
might establish the intriguing possibility of a 
distinct regulatory gene for ADA. 
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